Drug Targets: PDE10


PDE10 is a novel CNS drug target for schizophrenia treatments. Biotie, in collaboration with Pfizer, has demonstrated that inhibitors of PDE10 are active in experimental models relevant for schizophrenia. Data from these studies were recently presented at the American Chemical Society Fall National Meeting in Washington DC (August 2009) and at the Society for Neuroscience Annual Meeting in Chicago, IL (October 2009)

Biotie Therapies, in collaboration with Wyeth, has developed PDE10 compounds. This agreement continued from 2006 and now, Biotie has regained rights from Wyeth [Press Release]
Advertisements

About Guna

Interested to learn things around me
This entry was posted in Drug developments & targets. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s